DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer

JAMA Oncology

Volumn 2, Issue 5, 2016, Pages 655-662

  Boige, Valérie ^a,b   Vincent, Marc ^b   Alexandre, Philippe ^b   Tejpar, Sabine ^c   Landolfi, Stefania ^d,e   Le Malicot, Karine ^f   Greil, Richard ^f   Cuyle, Pieter Jan ^g   Yilmaz, Mette ^h   Faroux, Roger ⁱ   Matzdorff, Axel ^j   Salazar, Ramon ^k   Lepage, Côme ^l   Taieb, Julien ^m   Laurent Puig, Pierre ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Salzburger Landesklinik ^*  (Austria)

^g IMELDA HOSPITAL   (Belgium)

^h AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁱ Intensive Care Unit   (France)

^j Asklepios Clinic Uckermark   (Germany)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l Chu   (France)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010657688     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.5392     Document Type: Article

References (29)

1. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
2. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198-2204.
3. Ducreux M, Malka D, Mendiboure J, et al; Fédération Francophone de Cancérologie Digestive (FFCD) 2000-05 Collaborative Group. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol. 2011;12(11):1032-1044.
4. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer. 1995; 75(1):11-17.
5. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939-950.
6. Gross E, Busse B, Riemenschneider M, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One. 2008;3(12):e4003.
7. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000;10(3):217-223.
8. Ridge SA, Sludden J, Brown O, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol. 1998;46(2):151-156.
9. Braun MS, Richman SD, Thompson L, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009;27(33):5519-5528.
10. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640-645.
11. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32(10):1031-1039.
12. National Center for Biotechnology Information. Database of single nucleotide polymorphisms (dbSNP). (dbSNP Build ID: Human 137). http://www .ncbi.nlm.nih.gov/SNP/. Accessed January 10, 2012.
13. Taieb J, Tabernero J, Mini E, et al; PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(8):862-873.
14. Ahmed I, Tamouza R, DelordM, et al. Association between Parkinson's disease and the HLA-DRB1 locus. Mov Disord. 2012;27(9):1104-1110.
15. Rivera-Garcia C, Bristow SL, Yarnall S, et al. Validation of a multiplex genotyping platform using a novel genomic database approach [published online July 30, 2015]. Genet Med. doi:10.1038/gim .2015.101.
16. Stram DO. Tag SNP selection for association studies. Genet Epidemiol. 2004;27(4):365-374.
17. Tanaka T; International HapMap Consortium. The International HapMap Project. Nature. 2003; 426(6968):789-796.
18. Dmitrienko A, Tamhane AC. Gatekeeping procedures with clinical trial applications. Pharm Stat. 2007;6(3):171-180.
19. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575.
20. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12):dju298.
21. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 2013;73(6):1958-1968.
22. Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther. 2013;94(1):158-166.
23. Kleibl Z, Fidlerova J, Kleiblova P, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma. 2009;56(4):303-316.
24. Amstutz U, Farese S, Aebi S, Largiadèr CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009;10(6):931-944.
25. SchwabM, Zanger UM, Marx C, et al; German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13):2131-2138.
26. Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17(10):3455-3468.
27. Li Q, Liu Y, Zhang HM, et al. Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: ameta-analysis. Gastroenterol Res Pract. 2014;2014:827989.
28. Fernandez-Rozadilla C, Cazier JB, Moreno V, et al; EPICOLON Consortium. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2013;13(3): 209-217.
29. Won HH, Lee J, Park JO, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012;118(11):2828-2836.